Strategic License Agreements - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended				6 Months Ended
	Jul. 31, 2021	Jun. 30, 2021	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2021	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized			$ 688		$ 625		$ 886	$ 1,987
Current deferred revenue			930				930		$ 517
Contract liabilities			3,271				3,271		$ 2,696
Contract assets			0		0		0	0
Immedica Pharma AB
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research agreement date				2021-03
Non refundable payment received						$ 21,500
Percentage of payment for cost incurred in PIP trial						50.00%
Rate of revenue share						25.00%
Reimbursement	$ 3,000
Upfront payment						$ 21,500
Modified transaction price	25,100
Estimated amount incurred	$ 3,600
Allocation price net						12,000
Total deferred revenue			3,300		2,700		3,300	2,700
Current deferred revenue			900		300		900	300
Immedica Pharma AB | Peace Phase 3 Trial and Drug Supply
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized			$ 700				$ 900
Immedica Pharma AB | PEACE Trial and BLA Package
Research And Development Arrangement Contract To Perform For Others [Line Items]
Allocated amount of transaction price						9,600
Revenue recognized					$ 600			$ 2,000
Immedica Pharma AB | PIP Trial
Research And Development Arrangement Contract To Perform For Others [Line Items]
Allocated amount of transaction price						$ 3,500
Immedica Pharma AB | License Agreements
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized		$ 12,000
Immedica Pharma AB | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of payment for cost incurred in PIP trial						50.00%
Costs incurred in performing PIP the trial						$ 1,800